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Non-inferiority (NI) trials attempt to demonstrate that the
loss in efficacy by a new treatment compared to a standard
treatment is limited to a certain pre-specified margin,
usually compensated by some form of benefit in the form
of safety, ease in administration, tolerability, costs, etc. The
lack of mention of the benefit of the new treatment and its
importance have been pointed out recently.
The concept of ‘relative efficacy’ is highly relevant in
non-inferiority trials as the trade-off between the benefit
gained and the loss in efficacy plays an important part
in the non-inferiority claim. Applying the concept of
incremental cost effectiveness ratio, used widely in
health economics, in a non-inferiority setup, we propose
the benefit efficacy ratio as the ratio of gain in benefit to
loss in efficacy for the new treatment versus the standard
treatment. The ratio allows the benefit to contribute to
the statistical claim of non-inferiority and the patient /
physician to judge for oneself. We have studied the feasi-
bility of this concept among a set of NI trials published
in four major medical journals from 2005 to 2011.
Among 112 published NI trials, potential benefits could
be perceived in 89(80%) trials of which, data related to any
of the benefit was available in 56(63%) trial reports. Both
efficacy and benefit favoured the new treatment among 29
(54%) trials and both favoured the control treatment in 4
(7%). By its application in these trials, we show that the
benefit efficacy ratio could help overcome certain glitches
of non-inferiority.
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